The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Inactivated Influenza Virus Vaccine Market Research Report 2025
Synopsis
Highlights
The global Inactivated Influenza Virus Vaccine market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of Inactivated Influenza Virus Vaccine include CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer, Johnson & Johnson, Jiangsu Jindik Biotechnology Co., Ltd and Beijing Kexing Biological Products Co., Ltd, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for Inactivated Influenza Virus Vaccine in Hospital is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Whole Virus Vaccine, which accounted for % of the global market of Inactivated Influenza Virus Vaccine in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Inactivated Influenza Virus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Influenza Virus Vaccine.
The Inactivated Influenza Virus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Inactivated Influenza Virus Vaccine market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inactivated Influenza Virus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
CSL
GSK
Sanofi Pasteur
Mylan
AstraZeneca
Pfizer
Johnson & Johnson
Jiangsu Jindik Biotechnology Co., Ltd
Beijing Kexing Biological Products Co., Ltd
Jiangsu Kangrun Biotechnology Co., Ltd
Hualan Bio Vaccines Co., Ltd
Dalian Yalifeng Biopharmaceutical Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Changchun Institute of Biological Products Co., Ltd
Lanzhou Institute of Biological Products Co., Ltd
Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
Emmi Chengxin Biopharmaceutical Co., Ltd
Product Type Insights
Global markets are presented by Inactivated Influenza Virus Vaccine type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Inactivated Influenza Virus Vaccine are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Inactivated Influenza Virus Vaccine segment by Type
Whole Virus Vaccine
Subunit Vaccine
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Inactivated Influenza Virus Vaccine market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Inactivated Influenza Virus Vaccine market.
Inactivated Influenza Virus Vaccine segment by Application
Hospital
Clinic
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Inactivated Influenza Virus Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Inactivated Influenza Virus Vaccine industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Inactivated Influenza Virus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Highlights
The global Inactivated Influenza Virus Vaccine market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of Inactivated Influenza Virus Vaccine include CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer, Johnson & Johnson, Jiangsu Jindik Biotechnology Co., Ltd and Beijing Kexing Biological Products Co., Ltd, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for Inactivated Influenza Virus Vaccine in Hospital is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Whole Virus Vaccine, which accounted for % of the global market of Inactivated Influenza Virus Vaccine in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Inactivated Influenza Virus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Influenza Virus Vaccine.
The Inactivated Influenza Virus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Inactivated Influenza Virus Vaccine market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inactivated Influenza Virus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
CSL
GSK
Sanofi Pasteur
Mylan
AstraZeneca
Pfizer
Johnson & Johnson
Jiangsu Jindik Biotechnology Co., Ltd
Beijing Kexing Biological Products Co., Ltd
Jiangsu Kangrun Biotechnology Co., Ltd
Hualan Bio Vaccines Co., Ltd
Dalian Yalifeng Biopharmaceutical Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Changchun Institute of Biological Products Co., Ltd
Lanzhou Institute of Biological Products Co., Ltd
Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
Emmi Chengxin Biopharmaceutical Co., Ltd
Product Type Insights
Global markets are presented by Inactivated Influenza Virus Vaccine type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Inactivated Influenza Virus Vaccine are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Inactivated Influenza Virus Vaccine segment by Type
Whole Virus Vaccine
Subunit Vaccine
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Inactivated Influenza Virus Vaccine market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Inactivated Influenza Virus Vaccine market.
Inactivated Influenza Virus Vaccine segment by Application
Hospital
Clinic
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Inactivated Influenza Virus Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Inactivated Influenza Virus Vaccine industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Inactivated Influenza Virus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Index1 Inactivated Influenza Virus Vaccine Market Overview
1.1 Product Overview and Scope of Inactivated Influenza Virus Vaccine
1.2 Inactivated Influenza Virus Vaccine Segment by Type
1.2.1 Global Inactivated Influenza Virus Vaccine Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Whole Virus Vaccine
1.2.3 Subunit Vaccine
1.3 Inactivated Influenza Virus Vaccine Segment by Application
1.3.1 Global Inactivated Influenza Virus Vaccine Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Inactivated Influenza Virus Vaccine Market Size Estimates and Forecasts
1.4.1 Global Inactivated Influenza Virus Vaccine Revenue 2017-2028
1.4.2 Global Inactivated Influenza Virus Vaccine Sales 2017-2028
1.4.3 Inactivated Influenza Virus Vaccine Market Size by Region: 2017 Versus 2021 Versus 2028
2 Inactivated Influenza Virus Vaccine Market Competition by Manufacturers
2.1 Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2017-2022)
2.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Inactivated Influenza Virus Vaccine Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Inactivated Influenza Virus Vaccine Manufacturing Sites, Area Served, Product Type
2.5 Inactivated Influenza Virus Vaccine Market Competitive Situation and Trends
2.5.1 Inactivated Influenza Virus Vaccine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Inactivated Influenza Virus Vaccine Players Market Share by Revenue
2.5.3 Global Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Inactivated Influenza Virus Vaccine Retrospective Market Scenario by Region
3.1 Global Inactivated Influenza Virus Vaccine Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Inactivated Influenza Virus Vaccine Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.3.1 North America Inactivated Influenza Virus Vaccine Sales by Country
3.3.2 North America Inactivated Influenza Virus Vaccine Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.4.1 Europe Inactivated Influenza Virus Vaccine Sales by Country
3.4.2 Europe Inactivated Influenza Virus Vaccine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Inactivated Influenza Virus Vaccine Market Facts & Figures by Region
3.5.1 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Region
3.5.2 Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.6.1 Latin America Inactivated Influenza Virus Vaccine Sales by Country
3.6.2 Latin America Inactivated Influenza Virus Vaccine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.7.1 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country
3.7.2 Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Inactivated Influenza Virus Vaccine Historic Market Analysis by Type
4.1 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2017-2022)
4.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2017-2022)
4.3 Global Inactivated Influenza Virus Vaccine Price by Type (2017-2022)
5 Global Inactivated Influenza Virus Vaccine Historic Market Analysis by Application
5.1 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2017-2022)
5.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2017-2022)
5.3 Global Inactivated Influenza Virus Vaccine Price by Application (2017-2022)
6 Key Companies Profiled
6.1 CSL
6.1.1 CSL Corporation Information
6.1.2 CSL Description and Business Overview
6.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
6.1.5 CSL Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.2.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Corporation Information
6.3.2 Sanofi Pasteur Description and Business Overview
6.3.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.5.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Jiangsu Jindik Biotechnology Co., Ltd
6.8.1 Jiangsu Jindik Biotechnology Co., Ltd Corporation Information
6.8.2 Jiangsu Jindik Biotechnology Co., Ltd Description and Business Overview
6.8.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.8.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments/Updates
6.9 Beijing Kexing Biological Products Co., Ltd
6.9.1 Beijing Kexing Biological Products Co., Ltd Corporation Information
6.9.2 Beijing Kexing Biological Products Co., Ltd Description and Business Overview
6.9.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.9.5 Beijing Kexing Biological Products Co., Ltd Recent Developments/Updates
6.10 Jiangsu Kangrun Biotechnology Co., Ltd
6.10.1 Jiangsu Kangrun Biotechnology Co., Ltd Corporation Information
6.10.2 Jiangsu Kangrun Biotechnology Co., Ltd Description and Business Overview
6.10.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.10.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments/Updates
6.11 Hualan Bio Vaccines Co., Ltd
6.11.1 Hualan Bio Vaccines Co., Ltd Corporation Information
6.11.2 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments/Updates
6.12 Dalian Yalifeng Biopharmaceutical Co., Ltd
6.12.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Corporation Information
6.12.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.12.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.12.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments/Updates
6.13 Shanghai Institute of Biological Products Co., Ltd
6.13.1 Shanghai Institute of Biological Products Co., Ltd Corporation Information
6.13.2 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.13.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.13.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
6.14 Changchun Institute of Biological Products Co., Ltd
6.14.1 Changchun Institute of Biological Products Co., Ltd Corporation Information
6.14.2 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.14.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.14.5 Changchun Institute of Biological Products Co., Ltd Recent Developments/Updates
6.15 Lanzhou Institute of Biological Products Co., Ltd
6.15.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
6.15.2 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.15.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.15.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
6.16 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
6.16.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Corporation Information
6.16.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.16.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.16.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments/Updates
6.17 Emmi Chengxin Biopharmaceutical Co., Ltd
6.17.1 Emmi Chengxin Biopharmaceutical Co., Ltd Corporation Information
6.17.2 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.17.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.17.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments/Updates
7 Inactivated Influenza Virus Vaccine Manufacturing Cost Analysis
7.1 Inactivated Influenza Virus Vaccine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Inactivated Influenza Virus Vaccine
7.4 Inactivated Influenza Virus Vaccine Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Inactivated Influenza Virus Vaccine Distributors List
8.3 Inactivated Influenza Virus Vaccine Customers
9 Inactivated Influenza Virus Vaccine Market Dynamics
9.1 Inactivated Influenza Virus Vaccine Industry Trends
9.2 Inactivated Influenza Virus Vaccine Market Drivers
9.3 Inactivated Influenza Virus Vaccine Market Challenges
9.4 Inactivated Influenza Virus Vaccine Market Restraints
10 Global Market Forecast
10.1 Inactivated Influenza Virus Vaccine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Inactivated Influenza Virus Vaccine by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Inactivated Influenza Virus Vaccine by Type (2023-2028)
10.2 Inactivated Influenza Virus Vaccine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Inactivated Influenza Virus Vaccine by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Inactivated Influenza Virus Vaccine by Application (2023-2028)
10.3 Inactivated Influenza Virus Vaccine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Inactivated Influenza Virus Vaccine by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Inactivated Influenza Virus Vaccine by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Inactivated Influenza Virus Vaccine Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Inactivated Influenza Virus Vaccine Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Inactivated Influenza Virus Vaccine Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Inactivated Influenza Virus Vaccine Market Competitive Situation by Manufacturers in 2021
Table 5. Global Inactivated Influenza Virus Vaccine Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Inactivated Influenza Virus Vaccine Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Inactivated Influenza Virus Vaccine Manufacturing Sites and Area Served
Table 11. Manufacturers Inactivated Influenza Virus Vaccine Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Inactivated Influenza Virus Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Inactivated Influenza Virus Vaccine as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Inactivated Influenza Virus Vaccine Sales by Region (2017-2022) & (K Units)
Table 16. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2017-2022)
Table 17. Global Inactivated Influenza Virus Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2017-2022)
Table 19. North America Inactivated Influenza Virus Vaccine Sales by Country (2017-2022) & (K Units)
Table 20. North America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2017-2022)
Table 21. North America Inactivated Influenza Virus Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2017-2022)
Table 23. Europe Inactivated Influenza Virus Vaccine Sales by Country (2017-2022) & (K Units)
Table 24. Europe Inactivated Influenza Virus Vaccine Sales Market Share by Country (2017-2022)
Table 25. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Inactivated Influenza Virus Vaccine Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2017-2022)
Table 31. Latin America Inactivated Influenza Virus Vaccine Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2017-2022)
Table 33. Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2017-2022)
Table 39. Global Inactivated Influenza Virus Vaccine Sales by Type (2017-2022) & (K Units)
Table 40. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2017-2022)
Table 41. Global Inactivated Influenza Virus Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Inactivated Influenza Virus Vaccine Revenue Share by Type (2017-2022)
Table 43. Global Inactivated Influenza Virus Vaccine Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Application (2017-2022)
Table 45. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2017-2022)
Table 46. Global Inactivated Influenza Virus Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Inactivated Influenza Virus Vaccine Revenue Share by Application (2017-2022)
Table 48. Global Inactivated Influenza Virus Vaccine Price by Application (2017-2022) & (US$/Unit)
Table 49. CSL Corporation Information
Table 50. CSL Description and Business Overview
Table 51. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. CSL Inactivated Influenza Virus Vaccine Product
Table 53. CSL Recent Developments/Updates
Table 54. GSK Corporation Information
Table 55. GSK Description and Business Overview
Table 56. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. GSK Inactivated Influenza Virus Vaccine Product
Table 58. GSK Recent Developments/Updates
Table 59. Sanofi Pasteur Corporation Information
Table 60. Sanofi Pasteur Description and Business Overview
Table 61. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product
Table 63. Sanofi Pasteur Recent Developments/Updates
Table 64. Mylan Corporation Information
Table 65. Mylan Description and Business Overview
Table 66. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Mylan Inactivated Influenza Virus Vaccine Product
Table 68. Mylan Recent Developments/Updates
Table 69. AstraZeneca Corporation Information
Table 70. AstraZeneca Description and Business Overview
Table 71. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. AstraZeneca Inactivated Influenza Virus Vaccine Product
Table 73. AstraZeneca Recent Developments/Updates
Table 74. Pfizer Corporation Information
Table 75. Pfizer Description and Business Overview
Table 76. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Pfizer Inactivated Influenza Virus Vaccine Product
Table 78. Pfizer Recent Developments/Updates
Table 79. Johnson & Johnson Corporation Information
Table 80. Johnson & Johnson Description and Business Overview
Table 81. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Johnson & Johnson Inactivated Influenza Virus Vaccine Product
Table 83. Johnson & Johnson Recent Developments/Updates
Table 84. Jiangsu Jindik Biotechnology Co., Ltd Corporation Information
Table 85. Jiangsu Jindik Biotechnology Co., Ltd Description and Business Overview
Table 86. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 88. Jiangsu Jindik Biotechnology Co., Ltd Recent Developments/Updates
Table 89. Beijing Kexing Biological Products Co., Ltd Corporation Information
Table 90. Beijing Kexing Biological Products Co., Ltd Description and Business Overview
Table 91. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 93. Beijing Kexing Biological Products Co., Ltd Recent Developments/Updates
Table 94. Jiangsu Kangrun Biotechnology Co., Ltd Corporation Information
Table 95. Jiangsu Kangrun Biotechnology Co., Ltd Description and Business Overview
Table 96. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 98. Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments/Updates
Table 99. Hualan Bio Vaccines Co., Ltd Corporation Information
Table 100. Hualan Bio Vaccines Co., Ltd Description and Business Overview
Table 101. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 103. Hualan Bio Vaccines Co., Ltd Recent Developments/Updates
Table 104. Dalian Yalifeng Biopharmaceutical Co., Ltd Corporation Information
Table 105. Dalian Yalifeng Biopharmaceutical Co., Ltd Description and Business Overview
Table 106. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 108. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 109. Shanghai Institute of Biological Products Co., Ltd Corporation Information
Table 110. Shanghai Institute of Biological Products Co., Ltd Description and Business Overview
Table 111. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 113. Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 114. Changchun Institute of Biological Products Co., Ltd Corporation Information
Table 115. Changchun Institute of Biological Products Co., Ltd Description and Business Overview
Table 116. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 118. Changchun Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 119. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 120. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
Table 121. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 122. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 123. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 124. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Corporation Information
Table 125. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Description and Business Overview
Table 126. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 127. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 128. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 129. Emmi Chengxin Biopharmaceutical Co., Ltd Corporation Information
Table 130. Emmi Chengxin Biopharmaceutical Co., Ltd Description and Business Overview
Table 131. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 132. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 133. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 134. Production Base and Market Concentration Rate of Raw Material
Table 135. Key Suppliers of Raw Materials
Table 136. Inactivated Influenza Virus Vaccine Distributors List
Table 137. Inactivated Influenza Virus Vaccine Customers List
Table 138. Inactivated Influenza Virus Vaccine Market Trends
Table 139. Inactivated Influenza Virus Vaccine Market Drivers
Table 140. Inactivated Influenza Virus Vaccine Market Challenges
Table 141. Inactivated Influenza Virus Vaccine Market Restraints
Table 142. Global Inactivated Influenza Virus Vaccine Sales Forecast by Type (2023-2028) & (K Units)
Table 143. Global Inactivated Influenza Virus Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 144. Global Inactivated Influenza Virus Vaccine Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 145. Global Inactivated Influenza Virus Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 146. Global Inactivated Influenza Virus Vaccine Sales Forecast by Application (2023-2028) & (K Units)
Table 147. Global Inactivated Influenza Virus Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 148. Global Inactivated Influenza Virus Vaccine Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 149. Global Inactivated Influenza Virus Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 150. Global Inactivated Influenza Virus Vaccine Sales Forecast by Region (2023-2028) & (K Units)
Table 151. Global Inactivated Influenza Virus Vaccine Sales Market Share Forecast by Region (2023-2028)
Table 152. Global Inactivated Influenza Virus Vaccine Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 153. Global Inactivated Influenza Virus Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Inactivated Influenza Virus Vaccine
Figure 2. Global Inactivated Influenza Virus Vaccine Market Share by Type in 2021 & 2028
Figure 3. Whole Virus Vaccine Product Picture
Figure 4. Subunit Vaccine Product Picture
Figure 5. Global Inactivated Influenza Virus Vaccine Market Share by Application in 2021 & 2028
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Global Inactivated Influenza Virus Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Inactivated Influenza Virus Vaccine Market Size (2017-2028) & (US$ Million)
Figure 10. Global Inactivated Influenza Virus Vaccine Sales (2017-2028) & (K Units)
Figure 11. Inactivated Influenza Virus Vaccine Sales Share by Manufacturers in 2021
Figure 12. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Inactivated Influenza Virus Vaccine Players: Market Share by Revenue in 2021
Figure 14. Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2017-2022)
Figure 16. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region in 2021
Figure 17. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2017-2022)
Figure 18. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region in 2021
Figure 19. United States Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. U.K. Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Taiwan Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Mexico Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Brazil Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Argentina Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Colombia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Turkey Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Saudi Arabia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. UAE Inactivated Influenza Virus Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Sales Market Share of Inactivated Influenza Virus Vaccine by Type (2017-2022)
Figure 43. Manufacturing Cost Structure of Inactivated Influenza Virus Vaccine
Figure 44. Manufacturing Process Analysis of Inactivated Influenza Virus Vaccine
Figure 45. Inactivated Influenza Virus Vaccine Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
